Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro

#1915

Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.

Aim(s): The aim of this study is to characterize the interaction, optimal sequence and dose of SSA-based therapies (lanreotide) and MTT in PNEN.

Materials and methods: SSTR1-5 were evaluated in BON-1, QGP-1 and Ins1 NEN cells via immunoblot and qRT-PCR. The impact of lanreotide on intracellular signaling, hormone secretion and cell proliferation was measured in cell lysates and supernatants´.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Krug S

Authors: Krug S, Gress T, Theuerkorn K, Mordhorst J, Michl P,

Keywords: SSA, targeted therapies, SSTR,

To read the full abstract, please log into your ENETS Member account.